These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25026941)

  • 1. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
    Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
    Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
    Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization.
    Germano A; Rapa I; Volante M; De Francia S; Migliore C; Berruti A; Papotti M; Terzolo M
    Mol Cell Endocrinol; 2015 Feb; 401():105-10. PubMed ID: 25497672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.
    Baudin E; Pellegriti G; Bonnay M; Penfornis A; Laplanche A; Vassal G; Schlumberger M
    Cancer; 2001 Sep; 92(6):1385-92. PubMed ID: 11745214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
    Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
    Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results.
    Faggiano A; Leboulleux S; Young J; Schlumberger M; Baudin E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):110-3. PubMed ID: 16402938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells.
    Hescot S; Slama A; Lombès A; Paci A; Remy H; Leboulleux S; Chadarevian R; Trabado S; Amazit L; Young J; Baudin E; Lombès M
    Endocr Relat Cancer; 2013 Jun; 20(3):371-81. PubMed ID: 23696597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Practical use of o,p'DDD in adrenocortical carcinoma].
    Bacchetta J; Droz JP
    Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of mitotane and 1α,25-dihydroxyvitamin D
    Rubin B; Pilon C; Pezzani R; Rebellato A; Fallo F
    J Endocrinol Invest; 2020 Mar; 43(3):357-367. PubMed ID: 31587178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.
    Lehmann TP; Wrzesiński T; Jagodziński PP
    Mol Med Rep; 2013 Mar; 7(3):893-900. PubMed ID: 23254310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
    Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
    Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.
    Stigliano A; Cerquetti L; Borro M; Gentile G; Bucci B; Misiti S; Piergrossi P; Brunetti E; Simmaco M; Toscano V
    Endocr Relat Cancer; 2008 Mar; 15(1):1-10. PubMed ID: 18310271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia.
    Maher VM; Trainer PJ; Scoppola A; Anderson JV; Thompson GR; Besser GM
    Q J Med; 1992 Sep; 84(305):671-9. PubMed ID: 1480741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
    van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
    Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation.
    Cerquetti L; Sampaoli C; Amendola D; Bucci B; Misiti S; Raza G; De Paula U; Marchese R; Brunetti E; Toscano V; Stigliano A
    Int J Oncol; 2010 Aug; 37(2):493-501. PubMed ID: 20596677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of o,p'DDD therapy on endogenous ACTH concentrations in dogs with hypophysis-dependent hyperadrenocorticism.
    Nelson RW; Feldman EC; Shinsako J
    Am J Vet Res; 1985 Jul; 46(7):1534-7. PubMed ID: 2992329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma.
    Schteingart DE; Sinsheimer JE; Counsell RE; Abrams GD; McClellan N; Djanegara T; Hines J; Ruangwises N; Benitez R; Wotring LL
    Cancer Chemother Pharmacol; 1993; 31(6):459-66. PubMed ID: 8453685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.